The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.

Prestige Consumer Healthcare will release its fiscal 2026 second quarter and first half earnings on November 6, 2025, before market opening, with a conference call at 8:30 a.m. ET to discuss results.

Prestige Consumer Healthcare will present at the Barclays Global Consumer Staples Conference, offering a live webcast of the event for investors and interested parties.

Prestige Consumer Healthcare Inc. announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on June 11, 2025. The company reported record fiscal 2025 revenue and earnings, with organic revenue growth of 7.9% in Q4 and 1.2% in fiscal 2025.

Prestige Consumer Healthcare reported strong Q4 and fiscal 2025 results, with record revenues, organic growth, and improved profitability. The company provided an initial outlook for fiscal 2026, anticipating continued growth and earnings expansion.

Prestige Consumer Healthcare Inc. reported strong third quarter results, with record quarterly sales and earnings per share. The company's International OTC segment saw continued growth, while the Cough & Cold category declined. Prestige raised its full-year fiscal 2025 earnings outlook, citing robust free cash flow and reduced leverage.

The global ovulation test kit market is expected to grow from $226.7 million in 2024 to $429.5 million by 2034, driven by rising awareness of fertility health and technological advancements in digital ovulation tests.

The global dental floss market is expected to grow from $600 million in 2023 to $1074.50 million by 2033, driven by product innovations and increased awareness of oral hygiene. North America is expected to dominate the market during the forecast period.

Prestige Consumer Healthcare Inc. announced that it will release its fiscal 2025 first quarter earnings on August 8, 2024 and host a conference call to discuss the results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Oppenheimer analyst Brian Nagel upgraded the rating for NIKE, Inc. (NYSE:NKE) from Perform to Outperform, while raising the price target from $110 to $120. Nike shares gained 0.8% to close at $95.57 on Thursday. See how other analysts view this stock. Morgan Stanley analyst Carlos De Alba upgraded Alcoa Corporation (NYSE:AA) from Equal-Weight to Overweight and boosted the price target from $36.5 to $50. Alcoa shares ...Full story available on Benzinga.com

Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TARRYTOWN, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on Monday, June 10, 2024 at 1:30 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link: